Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2010

View Archived Issues

Further data from IMPACT trials of C1-INH in hereditary angioedema reported

Some clinical benefit of tremelimumab in phase II metastatic gastric/esophageal adenocarcinoma trial

Ixabepilone therapy linked to tumor regression in phase II metastatic renal cell carcinoma trial

Merck & Co. reports new potent and selective GPR109A agonist

GlaxoSmithKline claims novel antibacterial agents

NicOx describes novel nitric oxide-releasing steroids

Merck & Co. and NicOx claim new angiotensin II receptor antagonists

Myriad launched Prolaris to predict prostate cancer recurrence

Bristol-Myers highlights pipeline and biopharmaceutical strategy

SpePharm acquires rights to Savene and partners with Paladin

Kinex begins phase II trial of KX2-391 in bone-metastatic CRPC

Vaxart raises funds for development avian influenza vaccine

U.K. JCVI recommends Intercell's Japanese encephalitis vaccine Ixiaro

BioVex initiates phase I trial of genital herpes vaccine ImmunoVEX-HSV2

Biomoda and Amigenics announce collaboration

Stemgent invests in new biotechnology company Ubiquigent

DSMB supports continuation phase II Doxil trial in platinum-resistant ovarian cancer

Vertex identifies novel PKC-theta inhibitors

Foamix and Therapeutics collaborate to develop inflammatory skin disease therapies

Cell Therapeutics' phase III Opaxio trial in ovarian cancer to continue

Mount Sinai School of Medicine and Medisyn discover new potential Alzheimer's disease therapeutics

Rexahn submits protocol of phase IIb Zoraxel trial in erectile dysfunction to FDA

NeoStem and University of Michigan enter into sponsored research agreement

Merck & Co. presents update on late-stage pipeline following merger with Schering-Plough

Preliminary clinical data support the use of vaginal diazepam

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...